# ImmuPharma PLC Lupuzor™ Pivotal Phase III Study Update

- Link: https://www.directorstalkinterviews.com/immupharma-plc-lupuzor-pivotal-phase-iii-study-update/412747966
- Published: 2018-03-23T07:18:06+00:00
- Author: Giles Arbor

**ImmuPharma PLC** (LON:IMM), the specialist drug discovery and development company
announces that it has been informed by Simbec-Orion, the contract research organisation
conducting our Lupuzor™ pivotal Phase III trial study, that ‘database lock’ is expected
on 6 April 2018, with top line results announced by mid-April 2018.

Lupuzor™ is the Company’s lead programme for the potential breakthrough compound
for Lupus, a life threatening autoimmune disease.

> **Commenting on the trial update, Tim McCarthy, ImmuPharma PLC Chairman, said:**“
> With the continued robust safety record of Lupuzor™ achieved over this trial, 
> we look forward with confidence to reporting top line results in the near future.”

Share on:
